• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Many Diagnostics (E.G., Phenotypic Tests, Molecular Tests) Are Now Available to Detect Pathogens and Determine Antibiotic Susceptibility - Identifying Drug-Resistant Bacterial Infections

Posted on: Tuesday, 7 November 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c44675) has announced the addition of Identifying Drug-Resistant Bacterial Infections: Opportunity and Activity in the Diagnostics Arena to their offering.

Antibiotic drug resistance is a perpetual and growing source of medical need; however, diagnostics that can identify drug-resistant pathogens are limited in number. As bacteria develop resistance to more agents and classes of antibiotics, the need for rapid diagnostics that can provide diagnostic accuracy and help in patient management (i.e., by helping physicians administer appropriate therapy quickly) will grow urgent. Diagnostics companies should take heed of the significant market opportunity thus presented.

Get the Answers You Need to Shape Your Strategy

Antibiotic drug resistance continues to plague the community and hospital settings. Which setting is more lucrative for the uptake of diagnostics? What features are needed to penetrate these settings?

Currently, most diagnostics identifying drug-resistant pathogens are designed to detect methicillin-resistant Staphylococcus aureus (MRSA). Which pathogens represent future opportunities?

Many diagnostics (e.g., phenotypic tests, molecular tests) are now available to detect pathogens and determine antibiotic susceptibility. Where do future opportunities lie? What challenges must be overcome?

With the availability of better diagnostics for identification of resistant pathogens, treatment practices in the community and the hospital are likely to be impacted. How will the widespread use of diagnostics affect drug development and use of current drugs? Will it increase or decrease use of drugs such as daptomycin, linezolid, and tigecycline?

Scope

Impact of drug resistance and role of diagnostics: overview of resistance issues in the hospital and community settings and the crucial but limited role diagnostics play.

Key antibacterial drug-resistant pathogens: overview of key drug-resistant pathogens in the community and hospital settings, and their drug-resistance mechanisms.

Antibacterial diagnostic technologies: a review of technologies, including phenotypic and molecular tests as well as biological markers.

Key players: valuable profiles of important companies in the antibacterial diagnostics arena, including information on their current and emerging products.

Outlook: opportunities and challenges to developing antibacterial diagnostics and the effect of new antibacterial diagnostics on the pharmaceutical industry.

Content Outline:

Executive Summary

Strategic Considerations

Stakeholder Implications

Impact of Drug Resistance

Role of Diagnostics in Guiding Treatment

Key Antibacterial Drug-Resistant Pathogens

Staphylococcus

Sites of Infection

Mechanism of Resistance

Enterobacteriaceae

Sites of Infection

Mechanism of Resistance

Streptococcus

Sites of Infection

Mechanism of Resistance

Antibacterial Diagnostic Technologies: Status and Next Steps

Phenotypic Test Technology

Molecular Test Technology

Biological Markers

C-Reactive Protein

Procalcitonin

Other Biomarkers

Select Key Players in Antibacterial Diagnostics

Accelr8 Technology

Acolyte Biomedica

AdvanDx

Becton Dickinson

BioMerieux

Cepheid

HandyLab

Roche

Outlook for Diagnostics

Point-of-Care Testing

Impact of Diagnostics on Drug Development

Remaining Challenges

Bibliography

Tables

1. Mechanisms of Bacterial Resistance to Select Antibiotic Classes of Drugs

2. Key Outcome Parameters of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus (MRSA and MSSA)

3. Select Existing and Emerging Bacterial Detection and Susceptibility Diagnostic Technologies

4. Select Companies and Their Diagnostic Products

5. Advantages and Disadvantages of Developing Diagnostics for Antibacterial Resistance

Figures

1. Timeline of Discovery of New Classes of Antibiotics

2. Common Pathogens Implicated in Hospital-Acquired Infections

3. Mechanisms of Antibiotic Drug Resistance

4. Mechanisms of Transferring or Spreading Drug Resistance

Companies Mentioned:

Acolyte Biomedica

AdvanDx

Axis Shield

Becton Dickinson

Binax

BioMerieux

Bio-Rad

Brahms

Cellestis

Cepheid

Chemicon

Chiron

Cubist

Don Whitley Scientific

GeneOhm Sciences

Gen-Probe

Giles Scientific

HandyLab

Johnson & Johnson

King Pharmaceuticals

Launch

Mast

Minerva Biolabs

Nanogen

New Horizons Diagnostics

Nordic Pharma

Orion Diagnostica

Pfizer

Roche

Spectral

Wyeth

Zonda

For more information visit http://www.researchandmarkets.com/reports/c44675

Source: Decision Resources

Source: Business Wire

More News in this Category